

ANGPTL3/Angiopoietin-like 3 Protein, Cynomolgus (HEK293, His)

Cat. No.:	HY-P700954
Synonyms:	ANGPTL3; ANGPT5; ANG-5; Angiopoietin-5; FHBL2; ANL3; Angiopoietin-5; Angiopoietin-like Protein 3
Species:	Cynomolgus
Source:	HEK293
Accession:	A0A2K5UDC5 (S17-E460)
Gene ID:	102136264
Molecular Weight:	60-70 kDa

PROPERTIES

Biological Activity	Immobilized Cynomolgus ANGPTL3, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Anti-ANGPTL3 Antibody, hFc Tag with the EC ₅₀ of 10.1ng/ml determined by ELISA.
Appearance	Solution.
Formulation	Supplied as a 0.22µm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	N/A.
Storage & Stability	Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping	Shipping with dry ice.

DESCRIPTION

Background

The ANGPTL3/Angiopoietin-like 3 protein functions as a hepatokine, intricately involved in the regulation of lipid and glucose metabolism. Proposed to play a role in directing energy substrates towards storage or oxidative tissues in response to food intake, ANGPTL3 stimulates plasma triglycerides (TG) by inhibiting lipoprotein lipase (LPL) activity, leading to suppressed TG clearance. This effect is achieved through the recruitment of proprotein convertases PCSK6 and FURIN to LPL, resulting in cleavage and dissociation of LPL from the cell surface. Interestingly, this regulatory function does not require ANGPTL3 proteolytic cleavage, is mediated by the N-terminal domain, and remains unaffected by GPIHBP1. Additionally, ANGPTL3 inhibits endothelial lipase, elevating plasma levels of high-density lipoprotein (HDL) cholesterol and phospholipids. By binding to adipocytes, it activates lipolysis, releasing free fatty acids and glycerol. ANGPTL3 selectively suppresses LPL in oxidative tissues, directing very low-density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food, potentially cooperating with circulating, liver-derived ANGPTL8, and ANGPTL4 expression in WAT. It also contributes to lower plasma levels of low-density lipoprotein (LDL)-cholesterol independently of the canonical APOE and LDLR pathway. Moreover, ANGPTL3 may stimulate hypothalamic LPL activity, while in vitro, it inhibits LPL activity without effectiveness on GPIHBP1-stabilized LPL.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA